ストックスクリーナーアプリを入手
4.24
0.47%
0.02
Actuate Therapeutics Inc (ACTU) 最新ニュース
Actuate Therapeutics (NASDAQ:ACTU) Shares Down 3.6%Here's What Happened - MarketBeat
What is the long term forecast for GATES GROUP Inc. stockJuly 2025 Selloffs & AI Enhanced Trading Signals - baoquankhu1.vn
Published on: 2026-02-07 16:03:44 - baoquankhu1.vn
Actuate Therapeutics registers 1.33M shares for resale by investors - MSN
Patterns Watch: Is Actuate Therapeutics Inc benefiting from innovation trendsJuly 2025 Sentiment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Decliners Report: Is Actuate Therapeutics Inc benefiting from innovation trendsBreakout Watch & Daily Profit Maximizing Tips - baoquankhu1.vn
Becoming A Backbone Therapy: Lessons Learned With Actuate Therapeutics - Clinical Leader
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt - Yahoo Finance
Sectors Review: Will Actuate Therapeutics Inc stock benefit from M AJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - baoquankhu1.vn
Actuate Therapeutics plans phase 1/2 trial of oral cancer drug - Investing.com Nigeria
Aug EndMonth: Whats the beta of PHGE stockJuly 2025 Chart Watch & Verified Entry Point Detection - baoquankhu1.vn
Actuate Therapeutics, Inc. Announces Initiation of Phase 1/2 Clinical Trial for Elraglusib Tablet in Advanced Cancers - Quiver Quantitative
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers - manilatimes.net
Actuate Therapeutics Announces Plans to Expand Clinical - GlobeNewswire
Actuate Therapeutics, Inc. (NASDAQ:ACTU) Sees Significant Growth in Short Interest - MarketBeat
Risk Report: Why is VNCE stock going down2025 Technical Patterns & Detailed Earnings Play Strategies - baoquankhu1.vn
Merger Talk: Is Actuate Therapeutics Inc stock undervalued right nowInflation Watch & Fast Moving Stock Trade Plans - baoquankhu1.vn
Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to “Sell” - Defense World
Is Actuate Therapeutics Inc stock showing strong momentumPortfolio Return Report & Capital Protection Trade Alerts - baoquankhu1.vn
Actuate Therapeutics, Inc. (ACTU) Receives a Buy from Craig-Hallum - The Globe and Mail
Market Wrap: Does Actuate Therapeutics Inc have consistent dividend growth2025 Price Targets & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Published on: 2026-01-16 10:23:54 - baoquankhu1.vn
Published on: 2026-01-16 07:35:07 - baoquankhu1.vn
H.C. Wainwright reiterates Buy rating on Actuate Therapeutics stock at $20 - Investing.com UK
Price Action: Is Actuate Therapeutics Inc stock risky to hold nowPortfolio Gains Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Quarterly Recap: Can Actuate Therapeutics Inc stock deliver consistent earnings growthJuly 2025 WrapUp & Smart Money Movement Tracker - Bộ Nội Vụ
Actuate Therapeutics reports positive Phase 2 pancreatic cancer data - TipRanks
Actuate Therapeutics IncReports positive phase 2 trial data for elraglusibSEC filing - marketscreener.com
Actuate Therapeutics, Inc. Reports Positive Phase 2 Trial Results for Elraglusib - TradingView — Track All Markets
Actuate Therapeutics Reports Positive Phase 2 Study Results for Elraglusib Combination in Metastatic Pancreatic Cancer - Quiver Quantitative
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at AS - GlobeNewswire
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ... - Sahm
Todd Thomson Sells 280,000 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock - Defense World
Will Actuate Therapeutics Inc. stock benefit from green energy trendsJuly 2025 Trends & Long-Term Growth Stock Strategies - Улправда
Why Actuate Therapeutics Inc. stock is recommended by analysts2025 Pullback Review & Weekly Return Optimization Alerts - Улправда
Can Actuate Therapeutics Inc. stock sustain market leadershipJuly 2025 Final Week & Weekly Breakout Watchlists - Улправда
Insider at Actuate Therapeutics Makes a Major Move With Fresh Stock Sale - TipRanks
Actuate therapeutics director Kairos Venture Partners II, L.P. sells $1.6m in shares - Investing.com Nigeria
Actuate Therapeutics Insider Sold Shares Worth $1,624,000, According to a Recent SEC Filing - marketscreener.com
Actuate Therapeutics stock gets Buy rating after positive Phase 1 results - Investing.com Canada
Actuate Therapeutics stock gets Buy rating after positive Phase 1 results By Investing.com - Investing.com South Africa
Actuate Therapeutics stock rises on positive pediatric cancer trial data By Investing.com - Investing.com Nigeria
Actuate Therapeutics stock rises on positive pediatric cancer trial data - Investing.com
Actuate Therapeutics Reports Promising Initial Clinical Responses in Pediatric Cancers from Phase 1 Trial of Elraglusib - Quiver Quantitative
Experimental drug shrinks tough childhood tumors in early trial - Stock Titan
Analyst Downgrade: Is Actuate Therapeutics Inc stock supported by innovation pipelineTrade Performance Summary & Daily Profit Focused Stock Screening - moha.gov.vn
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% Higher – Here’s What Happened - Defense World
Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% HigherHere's What Happened - MarketBeat
Can Actuate Therapeutics' Elraglusib Overcome The Hurdles Of GSK-3ß Inhibition? - RTTNews
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):